

News
November 16, 2026
Windward Bio, a clinical-stage biotechnology company based in Basel, has priced a $175 million IPO on Nasdaq (excluding greenshoe). The Company is developing ultra-long-acting antibody medicines for conditions including asthma and COPD (chronic obstructive pulmonary disease), as well as atopic dermatitis. Its lead candidate, WIN378, is designed for twice-yearly dosing.
Novo Holdings invested in Windward in January 2025. In September 2026, the Company reported positive interim results for WIN378 in asthma and initiated Phase 3. Windward also announced a concurrent $50 million private placement with Sanofi, bringing expected gross proceeds from both transactions to $225 million.
Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: “Patients suffering from chronic autoimmune and inflammatory diseases need better options to both control their disease and improve convenience and compliance. Since Novo Holdings invested in January 2025, Windward Bio has made impressive progress in developing and advancing its long-acting clinical therapy pipeline. Congratulations to the Windward team, fellow investors and the board on this IPO milestone.”
Media Enquiries
Marie-Louise Jersin, Senior Communications Lead, maj@novo.dk